EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)

Tong Zhang, Di Yang, Liang Tang, Yu Hu

Molecular Medicine Reports · 2024

DOI: 10.3892/mmr.2024.13272 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Medicine Reports, 2024. Verfasst von Tong Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coronavirus disease 2019 pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) seriously affected global public health security. Studies on vaccines, neutralizing antibodies (NAbs) and small molecule antiviral drugs are currently ongoing. In particular, NAbs have emerged as promising therapeutic agents due to their well‑defined mechanism, high specificity, superior safety profile, ease of large‑scale production and simultaneous application for both prevention and treatment of viral infection. Numerous NAb therapeutics have entered the clinical research stages, demonstrating promising therapeutic and preventive effects. These agents have been used for outbreak prevention and control under urgent authorization processes. The present review summarizes the molecular targets of SARS‑CoV‑2‑associated NAbs and screening and identification techniques for NAb development. Moreover, the current shortcomings and challenges that persist with the use of NAbs are discussed. The aim of the present review is to offer a reference for the development of NAbs for any future emergent infectious diseases, including SARS‑CoV‑2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingSARS-CoV-2COVID-19Antibodies, ViralHumansAntiviral AgentsAnimals

Stichwörter der Autor:innen

nanobodyneutralizing antibodiesreceptor binding domainsevere acute respiratory syndrome coronavirus 2target therapy

Substanzen

Antibodies, NeutralizingAntibodies, ViralAntiviral Agents

Autor:innen und Institutionen

  • Department of Hematology, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.

Zitieren

APA

Zhang, T., Yang, D., Tang, L., & Hu, Y. (2024). Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Molecular Medicine Reports. https://doi.org/10.3892/mmr.2024.13272

Vancouver

Zhang T, Yang D, Tang L, Hu Y. Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Molecular Medicine Reports. 2024. doi:10.3892/mmr.2024.13272

BibTeX
@article{Zhang2024,
  author = {Zhang, Tong and Yang, Di and Tang, Liang and Hu, Yu},
  title = {Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)},
  journal = {Molecular Medicine Reports},
  year = {2024},
  doi = {10.3892/mmr.2024.13272}
}
Kostenlos starten →